PF-Atlas › Treatments › CD49a+ Tissue Resident Memory T-Cell Therapy
CD49a+ Tissue Resident Memory T-Cell Therapy
Adoptive transfer of lung-resident memory T cells reverses established fibrosis
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Preclinical
Evidence level
Level 3 (Preclinical)
Mechanism class
Adoptive transfer of lung-resident memory T cells reverses established fibrosis
Timeline
4-6 years
Risk profile
Medium
Developer
Multiple
Key researchers
Multiple
Overview
bioRxiv 2024: adoptive transfer of CD49a+ tissue resident memory cells reversed pulmonary fibrosis in mice. Novel approach — uses the lung own immune memory system rather than engineered cells. Potential for autologous therapy.
How CD49a+ Tissue Resident Memory T-Cell Therapy fits into IPF treatment
CD49a+ Tissue Resident Memory T-Cell Therapy is classified as Level 3 (Preclinical) at the Preclinical stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about CD49a+ Tissue Resident Memory T-Cell Therapy for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.